Cargando…

Effect of High Dose Rosuvastatin Loading before Percutaneous Coronary Intervention on Contrast-Induced Nephropathy

BACKGROUND AND OBJECTIVES: Contrast-induced nephropathy (CIN) is associated with increased morbidity and mortality. This observational, non-randomized study evaluated the effect of rosuvastatin loading before percutaneous coronary intervention (PCI) on the incidence of CIN in patients with acute cor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yun, Kyeong Ho, Lim, Jae Hong, Hwang, Kyo Bum, Woo, Sun Ho, Jeong, Jin Woo, Kim, Yong Cheol, Joe, Dai-Yeol, Ko, Jum Suk, Rhee, Sang Jae, Lee, Eun Mi, Oh, Seok Kyu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Society of Cardiology 2014
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4180606/ https://www.ncbi.nlm.nih.gov/pubmed/25278982 http://dx.doi.org/10.4070/kcj.2014.44.5.301

Ejemplares similares

Effect of High Dose Rosuvastatin Loading before Primary Percutaneous Coronary Intervention on Infarct Size in Patients with ST-Segment Elevation Myocardial Infarction
por: Kim, Ji Won, et al.
Publicado: (2014)

Erratum to: Effect of High Dose Rosuvastatin Loading before Primary Percutaneous Coronary Intervention on Infarct Size in Patients with ST-Segment Elevation Myocardial Infarction
por: Kim, Ji Won, et al.
Publicado: (2014)

Comparison of the Infarct Size between the Loading of Ticagrelor and Clopidogrel in Patients with Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
por: Yun, Kyeong Ho, et al.
Publicado: (2017)

Periprocedural Hemoglobin Drop and Contrast-Induced Nephropathy in Percutaneous Coronary Intervention Patients
por: Lee, Kang Hyu, et al.
Publicado: (2010)

Comparison of the Efficacy and Safety of Rosuvastatin/Ezetimibe Combination Therapy and Rosuvastatin Monotherapy on Lipoprotein in Patients With Type 2 Diabetes: Multicenter Randomized Controlled Study
por: Lee, Jiwoo, et al.
Publicado: (2020)

Correlations between High Platelet Reactivity, Extent of Coronary Artery Disease, and Periprocedural Myonecrosis in Patients with Acute Coronary Syndrome
por: Yun, Kyeong Ho, et al.
Publicado: (2017)

Comparison between rosuvastatin and atorvastatin for the prevention of contrast-induced nephropathy in patients with STEMI undergoing primary percutaneous coronary intervention
por: Firouzi, Ata, et al.
Publicado: (2018)

Antioxidative Activity after Rosuvastatin Treatment in Patients with Stable Ischemic Heart Disease and Decreased High Density Lipoprotein Cholesterol
por: Park, Do-Sim, et al.
Publicado: (2016)

Comparison of the Efficacy of Rosuvastatin versus Atorvastatin in Preventing Contrast Induced Nephropathy in Patient with Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention
por: Liu, Yong, et al.
Publicado: (2014)

Left Ventricular Thrombus Associated with Takotsubo Cardiomyopathy: A Cardioembolic Cause of Cerebral Infarction
por: Shin, Seoung-Nam, et al.
Publicado: (2011)

Long-Term Predictors of Clinical Events after Off-Label Use of Drug-Eluting Stent beyond 1 Year
por: Yun, Kyeong Ho, et al.
Publicado: (2013)

Rosuvastatin Reduces Blood Viscosity in Patients with Acute Coronary Syndrome
por: Jung, Lae-Young, et al.
Publicado: (2016)

Efficacy and Safety of Nebivolol and Rosuvastatin Combination Treatment in Patients with Concomitant Hypertension and Hyperlipidemia
por: Rhee, Moo-Yong, et al.
Publicado: (2020)

Diurnal variation of flow-mediated dilatation in healthy humans
por: Kim, Yong Cheol, et al.
Publicado: (2015)

Comparison of the incidence of contrast-induced nephropathy after primary PCI in patients receiving high-dose rosuvastatin and atorvastatin
por: Golshani, Samad, et al.
Publicado: (2022)

Comparison of the Efficacy of Rosuvastatin Monotherapy 20 mg with Rosuvastatin 5 mg and Ezetimibe 10 mg Combination Therapy on Lipid Parameters in Patients with Type 2 Diabetes Mellitus
por: Hwang, You-Cheol, et al.
Publicado: (2019)

Additive Beneficial Effects of Valsartan Combined with Rosuvastatin in the Treatment of Hypercholesterolemic Hypertensive Patients
por: Jang, Ji-Yong, et al.
Publicado: (2015)

Erratum to: Additive Beneficial Effects of Valsartan Combined with Rosuvastatin in the Treatment of Hypercholesterolemic Hypertensive Patients
por: Jang, Ji-Yong, et al.
Publicado: (2015)

The efficacy and safety of co-administration of fimasartan and rosuvastatin to patients with hypertension and dyslipidemia
por: Rhee, Moo-Yong, et al.
Publicado: (2017)

Moderate-Intensity Rosuvastatin Plus Ezetimibe Versus High-Intensity Rosuvastatin for Target Low-Density Lipoprotein Cholesterol Goal Achievement in Patients With Recent Ischemic Stroke: A Randomized Controlled Trial
por: Hong, Keun-Sik, et al.
Publicado: (2023)

Contrast-Induced Nephropathy in Patients Undergoing Percutaneous Coronary Intervention
por: Shoukat, Sana, et al.
Publicado: (2010)

Evaluation of contrast nephropathy in percutaneous treatment of chronic total occlusions
por: Aktürk, Erdal, et al.
Publicado: (2019)

Rosuvastatin attenuates contrast-induced nephropathy through modulation of nitric oxide, inflammatory responses, oxidative stress and apoptosis in diabetic male rats
por: Deng, Jie, et al.
Publicado: (2015)

Effect of high-dose rosuvastatin loading before percutaneous coronary intervention in Chinese patients with acute coronary syndrome: A systematic review and meta-analysis
por: Ye, Ziliang, et al.
Publicado: (2017)

The Number of Endothelial Progenitor Cells is Decreased in Patients With Non-Dipper Hypertension
por: Kim, Seunghwan, et al.
Publicado: (2012)

Can documented coronary vasospasm be the smoking gun in settling the etiology of sudden cardiac death?
por: Kim, Nam-Ho, et al.
Publicado: (2017)

Introduction of Wearable Device in Cardiovascular Field for Monitoring Arrhythmia
por: Kim, Nam Ho, et al.
Publicado: (2021)

Determination of Safe Contrast Media Dosage to Estimated Glomerular Filtration Rate Ratios to Avoid Contrast-Induced Nephropathy After Elective Percutaneous Coronary Intervention
por: Yoon, Hyuck-Jun, et al.
Publicado: (2011)

Factors Related to Major Bleeding After Ticagrelor Therapy: Results from the TICO Trial
por: Cho, Jae Young, et al.
Publicado: (2021)

Update of aristolochic acid nephropathy in Korea
por: Ban, Tae Hyun, et al.
Publicado: (2018)

Efficacy of short-term moderate or high-dose rosuvastatin in preventing contrast-induced nephropathy: A meta-analysis of 15 randomized controlled trials
por: Liang, Min, et al.
Publicado: (2017)

The Prevention of Contrast Induced Nephropathy by Sarpogrelate: a Prospective Randomized Controlled Clinical Trial
por: Ki, You-Jeong, et al.
Publicado: (2019)

Efficacy and safety of co‐administered telmisartan/amlodipine and rosuvastatin in subjects with hypertension and dyslipidemia
por: Jin, Xuan, et al.
Publicado: (2020)

Effect and Safety of Rosuvastatin in Acute Ischemic Stroke
por: Heo, Ji Hoe, et al.
Publicado: (2016)

Computed tomography-guided percutaneous hook wire localization of pulmonary nodular lesions before video-assisted thoracoscopic surgery: Highlighting technical aspects
por: Park, Jae Bum, et al.
Publicado: (2019)

Hemopericardium With Cardiac Tamponade After Percutaneous Vertebroplasty
por: Byoun, Jeong Tae, et al.
Publicado: (2022)

Beneficial Effects of Sarpogrelate and Rosuvastatin in High Fat Diet/Streptozotocin-Induced Nephropathy in Mice
por: Kim, Dong-hyun, et al.
Publicado: (2016)

Disconnection of the Rubber Tip of Arrow-Trerotola Percutaneous Thrombolytic Device
por: Kim, Han Myun, et al.
Publicado: (2014)

Hyperuricemia may be related to contrast-induced nephropathy after percutaneous coronary intervention
por: Demirkol, Sait, et al.
Publicado: (2013)

A Prospective Randomized, Double-Blind, Multi-Center, Phase III Clinical Trial Evaluating the Efficacy and Safety of Olmesartan/Amlodipine plus Rosuvastatin Combination Treatment in Patients with Concomitant Hypertension and Dyslipidemia: A LEISURE Study
por: Jo, Sang-Ho, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_708kupl36457u228i0ob3gllms